mwb raises target for Fresenius Medical Care stock to EUR 46.00

Published on 10/16/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 4.86 billion in the second quarter. Fresenius Medical Care stock costs EUR 39.57 on October 16, 2026, 0.28 percent above the Xetra close.

Leadership and earnings frame valuation

mwb research lifted its target from EUR 44.00 to EUR 46.00 on October 14, 2026.
Second-quarter revenue reached EUR 4.86 billion after EUR 4.79 billion a year earlier.
Fresenius Medical Care stock trades at EUR 39.57 at 10:42 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.28 percent above the Xetra close of October 15, 2026.
Third-quarter reporting is scheduled for November 3, 2026.

Aquarell-Illustration einer stilisierten Niere mit Wassertropfen in Blau- und Türkistönen — Eine zarte Aquarell-Illustration einer stilisierten menschlichen Niere mit Wassertropfen in Blau- und Türkistönen – symbolisch für die Kernkompetenz der Fresenius Medical Care AG (ISIN DE0005785802) in der Nierenersatztherapie, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) is trading at EUR 39.57 at Lang & Schwarz on October 16, 2026 at 10:42 a.m. CEST, 0.28 percent above the Xetra close of October 15, 2026 at EUR 39.46. On October 14, 2026, wallstreetONLINE reported that mwb research raised its price target from EUR 44.00 to EUR 46.00 and upgraded FMC from Hold to Buy. The target is 16.27 percent above the Lang & Schwarz price.

mwb raises the valuation bar

The analyst move comes after a difficult period for the dialysis provider. mwb research cut its 2026 revenue estimate by 2.50 percent to EUR 19.04 billion, while its higher target reflects the effect of ongoing share repurchases and expected efficiency gains, according to wallstreetONLINE.

Three milestones shape the setup

On August 4, 2026, the second-quarter report showed revenue of EUR 4.86 billion, versus EUR 4.79 billion in the second quarter of 2025. On October 7, 2026, Fresenius Medical Care announced that Shervin J. Korangy, aged 51, would become chief executive officer on October 12, 2026, succeeding Helen Giza, according to the Fresenius Medical Care release. On October 14, 2026, mwb research raised the target to EUR 46.00.

What does the target mean for margins?

The second-quarter figures provide the operating basis for the debate. Operating profit rose to EUR 466 million from EUR 425 million a year earlier, while the operating margin increased to 9.60 percent from 8.90 percent. Adjusted operating profit reached EUR 569 million, up from EUR 476 million, and the adjusted margin rose to 11.70 percent from 9.90 percent, according to the reported results published on October 5, 2026 by EuropeSays.

Reporting dates are already set

Fresenius Medical Care is scheduled to publish its third-quarter 2026 results on November 3, 2026, followed by the quarterly financial report on November 6, 2026, according to the company investor calendar. Those dates will test whether the margin progress from the second quarter can offset weaker treatment volumes and restructuring costs cited in the analyst assessment.

Stock stays below its yearly high

The Lang & Schwarz price is 16.77 percent below the 52-week high of EUR 47.54 and 14.46 percent above the 52-week low of EUR 34.57. The market capitalization is EUR 10.5 billion, based on the October 16, 2026 quote.

Fresenius Medical Care was trading at EUR 39.57 at Lang & Schwarz on October 16, 2026 at 10:42 a.m. CEST, 0.28 percent above the Xetra close of October 15, 2026 at EUR 39.46. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.